FLG and Alzheimer disease: This is particularly relevant given IL-33’s central role in AD, where it activates type 2 innate lymphoid cells (ILC2s), drives Th2-skewed responses, regulates mast cell function, and impairs skin barrier integrity by downregulating epidermal differentiation markers such as filaggrin (47–51).